ArticleClinical epigenetics2026
Early detection of gastric cancer with the assistance of cell-free DNA fragmentomics.
Article in Clinical epigenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immune response to DNA and RNA: structural insights, molecular mechanisms, and therapeutic targeting.Molecular biomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundGastric cancer remains one of the most prevalent malignancies globally. As early-stage gastric cancer is typically asymptomatic or presents with non-specific symptoms, most patients are diagnosed at advanced stages, leading to poor survival outcomes. Effective early detection strategies are important for reducing gastric cancer-related mortality. In this study, we developed a non-invasive assay utilizing cell-free DNA to distinguish patients with early-stage gastric cancer from healthy individuals.
resultsWe performed low-depth whole genome sequencing to profile cell-free DNA and extracted three distinct features: fragment size patterns, coverage at transcription factor binding sites, and methylation-based profiles. These features were integrated via machine learning to construct a stacked ensemble model. The study included a training cohort (108 gastric cancer patients and 108 healthy controls), a temporally independent validation cohort (79 patients and 79 healthy controls), and an external validation cohort recruited from two independent centers (136 patients and 136 healthy controls). The ensemble model demonstrated robust performance, achieving area under the curve values of 0.986, 0.978, and 0.967 in the training, validation, and external cohorts, respectively. Specificity and sensitivity were 98.1% and 89.8% in the training cohort, 97.5% and 87.6% in the validation cohort, and 96.3% and 87.5% in the external cohort. Notably, the sensitivity for detecting stage I gastric cancer exceeded 85% across all cohorts.
conclusionsBy integrating multi-dimensional cell-free DNA fragmentomic features, this assay provides accurate, non-invasive detection of gastric cancer, particularly at early stages. While its performance was high, the specificity reported here may be overestimated due to the use of a strictly screened healthy control group. Nevertheless, this fragmentomic-based approach represents a promising tool to complement existing screening strategies, potentially improving early diagnosis rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.